214 related articles for article (PubMed ID: 31419332)
1. Modeling Progress Toward Elimination of Hepatitis B in Australia.
McCulloch K; Romero N; MacLachlan J; Allard N; Cowie B
Hepatology; 2020 Apr; 71(4):1170-1181. PubMed ID: 31419332
[TBL] [Abstract][Full Text] [Related]
2. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States.
Ogawa E; Yeo YH; Dang N; Le MH; Jeong D; Tran S; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2020 Apr; 3(4):e201844. PubMed ID: 32271388
[TBL] [Abstract][Full Text] [Related]
4. Improving the identification of priority populations to increase hepatitis B testing rates, 2012.
van Gemert C; Wang J; Simmons J; Cowie B; Boyle D; Stoove M; Enright C; Hellard M
BMC Public Health; 2016 Feb; 16():95. PubMed ID: 26832144
[TBL] [Abstract][Full Text] [Related]
5. The current and future burden of hepatitis B in Switzerland: a modelling study.
Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
[TBL] [Abstract][Full Text] [Related]
6. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
7. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
9. A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein ST; Zhou F; Hadler SC; Bell BP; Mast EE; Margolis HS
Int J Epidemiol; 2005 Dec; 34(6):1329-39. PubMed ID: 16249217
[TBL] [Abstract][Full Text] [Related]
10. The burden of chronic hepatitis B virus infection in Australia, 2011.
MacLachlan JH; Allard N; Towell V; Cowie BC
Aust N Z J Public Health; 2013 Oct; 37(5):416-22. PubMed ID: 24090323
[TBL] [Abstract][Full Text] [Related]
11. The Changing Global Epidemiology of Hepatocellular Carcinoma.
Caines A; Selim R; Salgia R
Clin Liver Dis; 2020 Nov; 24(4):535-547. PubMed ID: 33012444
[TBL] [Abstract][Full Text] [Related]
12. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
14. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
15. A global investment framework for the elimination of hepatitis B.
Howell J; Pedrana A; Schroeder SE; Scott N; Aufegger L; Atun R; Baptista-Leite R; Hirnschall G; 't Hoen E; Hutchinson SJ; Lazarus JV; Olufunmilayo L; Peck R; Sharma M; Sohn AH; Thompson A; Thursz M; Wilson D; Hellard M
J Hepatol; 2021 Mar; 74(3):535-549. PubMed ID: 32971137
[TBL] [Abstract][Full Text] [Related]
16. Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
Taye BW; Valery PC; Clark PJ
J Viral Hepat; 2022 Oct; 29(10):868-878. PubMed ID: 35748684
[TBL] [Abstract][Full Text] [Related]
17. The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment.
Allard NL; MacLachlan JH; Cowie BC
Aust N Z J Public Health; 2015 Jun; 39(3):255-9. PubMed ID: 25716519
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus infection in children.
Komatsu H; Inui A
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):427-50. PubMed ID: 25724218
[TBL] [Abstract][Full Text] [Related]
19. Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016).
Lu M; Li J; Zhou Y; Rupp LB; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Trudeau S; Gordon SC;
J Clin Gastroenterol; 2022 Mar; 56(3):273-279. PubMed ID: 33780209
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
